Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan S Coates

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
The Lancet. Oncology|December 18, 2007
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialBirgitte B Rasmussen, Meredith M Regan, Anne E Lykkesfeldt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozoleGiuseppe Viale, Anita Giobbie-Hurder, Meredith M Regan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2017
Long-Term Follow-Up of the Intergroup Exemestane StudyJames P Morden, Isabel Alvarez, Gianfilippo Bertelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Kathryn P Gray, Shari Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancerMartin R Stockler, Vernon J Harvey, Prudence A Francis, et al.
Breast Cancer Research and Treatment|November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR TrialIrene L Wapnir, Karen N Price, Stewart J Anderson, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
The Lancet. Oncology|January 21, 2014
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trialStefan Aebi, Shari Gelber, Stewart J Anderson, et al.
Breast Cancer Research and Treatment|October 24, 2015
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trialsMeredith M Regan, Olivia Pagani, Prudence A Francis, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
The Lancet. Oncology|December 18, 2007
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialBirgitte B Rasmussen, Meredith M Regan, Anne E Lykkesfeldt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozoleGiuseppe Viale, Anita Giobbie-Hurder, Meredith M Regan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2017
Long-Term Follow-Up of the Intergroup Exemestane StudyJames P Morden, Isabel Alvarez, Gianfilippo Bertelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Kathryn P Gray, Shari Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancerMartin R Stockler, Vernon J Harvey, Prudence A Francis, et al.
Breast Cancer Research and Treatment|November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR TrialIrene L Wapnir, Karen N Price, Stewart J Anderson, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
The Lancet. Oncology|January 21, 2014
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trialStefan Aebi, Shari Gelber, Stewart J Anderson, et al.
Breast Cancer Research and Treatment|October 24, 2015
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trialsMeredith M Regan, Olivia Pagani, Prudence A Francis, et al.
Pageof 11